Clinical Trial Detail

NCT ID NCT03064854
Title PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab

Canakinumab + Carboplatin + Spartalizumab

Carboplatin + Paclitaxel + Spartalizumab

Cisplatin + Pemetrexed Disodium + Spartalizumab

Cisplatin + Gemcitabine + Spartalizumab

Age Groups: adult senior

Additional content available in CKB BOOST